enoximone


Also found in: Wikipedia.

enoximone

 [en-ok´sĭ-mōn]
a vasodilator similar to inamrinone; used as a cardiotonic in the short-term management of congestive heart failure, administered intravenously.

enoximone

/enox·i·mone/ (en-ok´sĭ-mōn) a phosphodiesterase inhibitor similar to inamrinone; used as a cardiotonic in the short-term management of congestive heart failure, administered intravenously.

enoximone

[enok′sĭmōn]
a vasodilator similar to inamrinone, used as a cardiotonic in the short-term management of congestive heart failure. It is administered intravenously.

enoximone

A PHOSPHODIESTERASE INHIBITOR drug used to improve the heart's action in HEART FAILURE. A brand name is Perfan.
References in periodicals archive ?
Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial.
Anaesthetists commonly administer [beta]-adrenergic agonists (dobutamine, dopamine or adrenaline) as first-line inotropic therapy, with secondary addition of milrinone or enoximone before the institution of mechanical support.
Intravenous enoximone is a positive inotropic agent indicated for the treatment of acute decompensated heart failure and various uses in the cardiac surgery setting.
TORONTO -- Low doses of oral enoximone, an investigational positive inotrope, may help safely wean advanced heart failure patients from intravenous inotropes, according to data from a phase III randomized trial.
The decrease in expenses from 2005 was primarily due to the discontinuation of the development of enoximone, which was partially offset by growth in expenses related to darusentan and increased stock-based compensation expense.
Beta blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Weaning from CPB was achieved using atrial pacing, IABP, enoximone and noradrenaline.
The decrease in expenses for the 2005 period was primarily due to the termination of the development of enoximone capsules.
The decrease in expenses for 2005 was primarily due to the discontinuation of the development of enoximone capsules, which was largely offset by growth in expenses related to ambrisentan.
While the results of the ESSENTIAL trials did not support continuation of the enoximone development program, we continue to be excited by the opportunities that our two current product candidates present to positively impact the treatment of significant cardiovascular disorders.
We had high hopes for oral enoximone as a new therapy for the millions of patients who suffer from the debilitating symptoms of advanced chronic heart failure.